Search Results - kazusa+ishii

2 Results

Sort By:

T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias

Summary: NCI seeks parties interested in licensing to further develop a collection of novel anti-CD20 TCRs that can be used to treat CD20 positive lymphomas and leukemias. Description of Technology: CD20 is a protein expressed by wide ranges of lymphoid malignancies originating from B cells but not by indispensable normal tissues, making it an attractive...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Kazusa Ishii, Christian Hinrichs

Keywords(s): Acute Lymphoblastic Leukemia, ALL, CD20, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Resistant B-lymphoid malignancies, T-Cell Receptor, TCR

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias

Description of Technology: CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Kazusa Ishii, Christian Hinrichs

Keywords(s): Acute Lymphoblastic Leukemia, ALL, B cells, CD22, Cellular Immunotherapy, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Relapsed / refractory B-Lymphoid Malignancies, T-Cell Receptor, TCR

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology